Evidence map›Paper›PMID 37091588›Full record

ArticleBrain communications2023

Nogo receptor-Fc delivered by haematopoietic cells enhances neurorepair in a multiple sclerosis model.

Sining Ye, Paschalis Theotokis, Jae Young Lee, Min Joung Kim, Danica Nheu, Olivia Ellen, Thomas Bedford, Padmanabhan Ramanujam, David K Wright, Stuart J McDonald and 10 more

Open access · goldAbstract read
In one paragraph

Article in Brain communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 6 countries.

Sining YeDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
Paschalis TheotokisB', Department of Neurology, Laboratory of Experimental Neurology and Neuroimmunology, AHEPA University Hospital, Stilponos Kiriakides str. 1, 54636 Thessaloniki, Macedonia, Greece.ORCID https://orcid.org/0000-0001-8607-6695
Jae Young LeeToolGen Inc., Gangseo-gu, 07789 Seoul, Korea.
Min Joung KimDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
Danica NheuDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
Olivia EllenDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
Thomas BedfordDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.ORCID https://orcid.org/0000-0001-6040-6246
Padmanabhan RamanujamDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
David K WrightDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.ORCID https://orcid.org/0000-0002-7535-8651
Stuart J McDonaldDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
Amani AlrehailiDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
Maha BakhuraysahDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
Jung Hee KangDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
Christopher SiatskasSTEMCELL Technologies Inc., Vancouver, British Columbia V6A 1B6, Canada.
Cedric S TremblayAustralian Centre for Blood Diseases, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
David J CurtisAustralian Centre for Blood Diseases, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
Nikolaos GrigoriadisB', Department of Neurology, Laboratory of Experimental Neurology and Neuroimmunology, AHEPA University Hospital, Stilponos Kiriakides str. 1, 54636 Thessaloniki, Macedonia, Greece.
Mastura MonifDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.
Stephen M StrittmatterProgram in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, CT 06536, USA.ORCID https://orcid.org/0000-0001-8188-3092
Steven PetratosDepartment of Neuroscience, Central Clinical School, Monash University, Prahran, Victoria 3004, Australia.ORCID https://orcid.org/0000-0003-1211-4577
Monash University · AUAHEPA University Hospital · GRTaif University · SAStemcell Technologies · CAThe Alfred Hospital · AUToolGen (South Korea) · KRYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nogo receptor 1 is the high affinity receptor for the potent myelin-associated inhibitory factors that make up part of the inflammatory extracellular milieu during experimental autoimmune encephalomyelitis. Signalling through the Nogo receptor 1 complex has been shown to be associated with axonal degeneration in an animal model of multiple sclerosis, and neuronal deletion of this receptor homologue, in a disease specific manner, is associated with preserving axons even in the context of neuroinflammation. The local delivery of Nogo receptor(1-310)-Fc, a therapeutic fusion protein, has been successfully applied as a treatment in animal models of spinal cord injury and glaucoma. As multiple sclerosis and experimental autoimmune encephalomyelitis exhibit large numbers of inflammatory cell infiltrates within the CNS lesions, we utilized transplantable haematopoietic stem cells as a cellular delivery method of the Nogo receptor(1-310)-Fc fusion protein. We identified CNS-infiltrating macrophages as the predominant immune-positive cell type that overexpressed myc-tagged Nogo receptor(1-310)-Fc fusion protein at the peak stage of experimental autoimmune encephalomyelitis. These differentiated phagocytes were predominant during the extensive demyelination and axonal damage, which are associated with the engulfment of the protein complex of Nogo receptor(1-310)-Fc binding to myelin ligands. Importantly, mice transplanted with haematopoietic stem cells transduced with the lentiviral vector carrying Nogo receptor(1-310)-Fc and recovered from the peak of neurological decline during experimental autoimmune encephalomyelitis, exhibiting axonal regeneration and eventual remyelination in the white matter tracts. There were no immunomodulatory effects of the transplanted, genetically modified haematopoietic stem cells on immune cell lineages of recipient female mice induced with experimental autoimmune encephalomyelitis. We propose that cellular delivery of Nogo receptor(1-310)-Fc fusion protein through genetically modified haematopoietic stem cells can modulate multifocal experimental autoimmune encephalomyelitis lesions and potentiate neurological recovery.

Indexed as

axonal regenerationexperimental autoimmune encephalomyelitishaematopoietic stem cellsNogo receptor-Fcremyelination

Identifiers

PMID37091588
PMCPMC10116608
OpenAlexW4362594134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.